NovaBay Pharmaceuticals (NBY)
(Real Time Quote from BATS)
$0.64 USD
+0.14 (28.80%)
Updated Sep 20, 2024 11:54 AM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
NBY 0.64 +0.14(28.80%)
Will NBY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NBY
NovaBay Pharmaceuticals (NBY) Shows Fast-paced Momentum But Is Still a Bargain Stock
NBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NBY
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
NovaBay Pharmaceuticals to sell Avenova assets for $9.5M
Niobium-Titanium Alloy Demonstrates Its Strong Market Potential in the Fabrication of Fuel Cells
NioBay Metals Receives Authorization to Drill on Zone 1 of its Foothills Property